**Supplementary Fig. S5**. Kaplan-Meier estimate of progression-free survival for patients with and without *ESR1* mutations in baseline ctDNA samples collected from the 1400 mg dose group. *ESR1* data was available for 36 of 36 patients dosed at 1400 mg.